Holen Sie sich die Stockscreener-App
16.27
8.39%
-1.49
Handel nachbörslich:
16.28
0.01
+0.06%
Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten
65,800-share Form 144 filed by AVTX (NASDAQ: AVTX) - stocktitan.net
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Avalo Therapeutics (NASDAQ:AVTX) Earns Market Outperform Rating from Analysts at Citizens Jmp - marketbeat.com
Citizens Initiates Coverage on Avalo Therapeutics (AVTX) with Ma - GuruFocus
Citizens JMP Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $52 - Moomoo
Wall Street analysts predict an 113.34% upside in Avalo Therapeutics (AVTX): Here's what you should know - MSN
Citizens initiates Avalo Therapeutics stock with outperform rating By Investing.com - Investing.com India
Citizens initiates Avalo Therapeutics stock with outperform rating - investing.com
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
AVTX Technical Analysis & Stock Price Forecast - Intellectia AI
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Insider Sell Alert: Christopher Sullivan Sells Shares of Avalo T - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock - marketbeat.com
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares - marketbeat.com
Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares - MarketBeat
Avalo Therapeutics CFO Sullivan sells $270k in stock - investing.com
Avalo Therapeutics (AVTX) CMO Doyle Mittie sells $10,864 in stock - investing.com
Avalo Therapeutics (AVTX) CFO executes Rule 10b5-1 stock sale plan - stocktitan.net
Avalo Therapeutics (AVTX) CMO exercises options, sells 679 pre-planned shares - stocktitan.net
Wall Street experts anticipate Avalo Therapeutics (AVTX) could surge by 113.34%: Key Insights You Need to Know - Bitget
Avalo Therapeutics, Inc. (AVTX) stock price, news, quote and history - Yahoo Finance Singapore
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know - Yahoo Finance
[144] Avalo Therapeutics, Inc. SEC Filing - stocktitan.net
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,339 options - stocktitan.net
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,370 vested options - stocktitan.net
Logos Global (AVTX) discloses 1,285,000-share position, including options - stocktitan.net
AVTX SEC FilingsAvalo Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Avalo Therapeutics (AVTX) director acquires 3,166 shares via RSU vesting - stocktitan.net
Avalo Therapeutics (AVTX) director exercises 3,166 RSUs, holds 6,333 shares - stocktitan.net
Director at Avalo Therapeutics (AVTX) converts 3,166 RSUs to stock - stocktitan.net
Avalo Therapeutics (AVTX) CEO exercises RSUs, shares withheld for taxes - stocktitan.net
Avalo Therapeutics (AVTX) CFO nets shares from RSU vesting and tax settlement - stocktitan.net
Director at Avalo Therapeutics (AVTX) exercises 3,166 RSUs into common stock - stocktitan.net
Director at Avalo Therapeutics (AVTX) gains 3,166 common shares - stocktitan.net
Growth Recap: Can Avalo Therapeutics Inc grow without external fundingMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
US Stocks Recap: Can Avalo Therapeutics Inc outperform under higher oil pricesMarket Sentiment Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to “Hold” at Wall Street Zen - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to "Hold" at Wall Street Zen - marketbeat.com
Volatility Watch: What analysts say about Avalo Therapeutics Inc stock2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
HC Wainwright Has Positive Outlook for AVTX Q1 Earnings - Defense World
Avalo Therapeutics' Jonathan Goldman and Mitchell Chan to Not Stand for Re-election - TradingView
Two Avalo Therapeutics (AVTX) directors to step down after 2026 meeting - stocktitan.net
Avalo Therapeutics, Inc. Announces Departure of Directors Dr. Jonathan Goldman and Mitchell Chan - marketscreener.com
HC Wainwright Issues Positive Outlook for AVTX Earnings - marketbeat.com
Aug Macro: Is Avalo Therapeutics Inc a potential multi bagger2026 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $40.00 at HC Wainwright - Defense World
What date does Avalo Therapeutics's (AVTX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Avalo Therapeutics price target to $40 on trial confidence - Investing.com Australia
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
AVTX: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Avalo Therapeutics 2025 Financial Review - AlphaStreet
Is Avalo Therapeutics Inc a potential multi bagger2026 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX St - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research - MarketBeat
Mizuho Securities Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $39 - Moomoo
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):